Volume 84, Issue 5, Pages (November 2013)

Slides:

Advertisements

Similar presentations

Acid-base profile in patients on PD

Advertisements

Home care assistance and the utilization of peritoneal dialysis

Volume 85, Issue 4, Pages (April 2014)

Volume 70, Pages S138-S145 (November 2006)

Use of hemodialysis and hemoperfusion in poisoned patients

Volume 85, Issue 4, Pages (April 2014)

No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease Kevin E. Chan, Ravi I. Thadhani,

Acid-base profile in patients on PD

End-stage renal disease in developing countries

Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis James F. Medcalf, Kevin P.G.

Volume 84, Issue 1, Pages (July 2013)

Long-term follow-up of patients randomized to biocompatible or conventional peritoneal dialysis solutions show no difference in peritonitis or technique.

Impact of new dialysis solutions on peritonitis rates

Incremental peritoneal dialysis: Effects on the choice of dialysis modality, residual renal function and adequacy G. Viglino, L. Neri, S. Barbieri Kidney.

The risk of hospitalization and modality failure with home dialysis

Fibrin plug Kidney International Volume 78, Issue 9, (November 2010)

Volume 77, Issue 1, Pages 6-8 (January 2010)

Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials Suetonia C. Palmer, PhD, Sharon Gardner, MA, Marcello Tonelli,

Ho-Han Wu, Szu-Yuan Li, Wu-Chang Yang Kidney International

Fluid overload and residual renal function in peritoneal dialysis: the proof of the pudding is in the eating Wim Van Biesen, Achim Jörres Kidney International

Volume 73, Issue 4, Pages (February 2008)

Volume 78, Issue 6, Pages (September 2010)

Volume 80, Issue 9, Pages (November 2011)

Volume 85, Issue 1, Pages (January 2014)

Methotrexate in the urine

Comorbidity and confounding in end-stage renal disease

Early mortality in dialysis and adequacy of predialysis renal care: the picture is more complex than we thought Nicolas Rognant, Maurice Laville Kidney.

Volume 77, Issue 2, Pages (January 2010)

Sankar D. Navaneethan, MD, MPH, Suetonia C. Palmer, MBChB, Jonathan C

U-shaped effect of eGFR and mortality

Volume 73, Pages S5-S17 (April 2008)

Body size and outcomes on peritoneal dialysis in the United States

Volume 76, Issue 11, Pages (December 2009)

Volume 76, Issue 5, Pages (September 2009)

Volume 73, Issue 12, Pages (June 2008)

Peritoneal dialysis adequacy and risk of death

Volume 76, Issue 6, Pages (September 2009)

Yijian Huang, Rebecca Zhang, Steven D. Culler, Nancy G. Kutner

Microbiology and outcomes of peritonitis in North America

Alternate-day dialysis may be needed for hemodialysis patients

Nephrology Crossword: Peritoneal Dialysis

Randomized controlled study of biocompatible peritoneal dialysis solutions: Effect on residual renal function S.L.S. Fan, T. Pile, S. Punzalan, M.J.

Hepatitis C treatment in patients with kidney disease

Nephrology Crossword: Glomerulonephritis

Quality of life in peritoneal dialysis patients: Decline over time and association with clinical outcomes Sr. Anne B. Bakewell, Rob M. Higgins, Mair.

Vitamin D in chronic kidney disease: is the jury in?

Volume 82, Issue 9, Pages (November 2012)

Carmine Zoccali, Francesca Mallamaci Kidney International

Peter G. Blake, Arsh K. Jain, Sechelle Yohanna Kidney International

Does equal care give equal outcomes?

Volume 83, Issue 5, Pages (May 2013)

The Danish Renal Biopsy Register

Volume 80, Issue 10, Pages (November 2011)

Adequacy of automated peritoneal dialysis with and without manual daytime exchange: A randomized controlled trial D. Demetriou, A. Habicht, M. Schillinger,

Volume 80, Issue 10, Pages (November 2011)

Charles A. Herzog Kidney International

Volume 83, Issue 3, Pages (March 2013)

Volume 86, Issue 2, Pages (August 2014)

Victoria R. Briggs, Badri M. Shrestha, Martin E. Wilkie

Volume 81, Issue 8, Pages (April 2012)

Volume 70, Issue 10, Pages (November 2006)

The International Pediatric Peritonitis Registry: Starting to walk

Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials Suetonia C. Palmer, PhD, Sharon Gardner, MA, Marcello Tonelli,

Antioxidant therapy in hemodialysis patients: a systematic review

Hemodialysis access failure: a call to action—revisited

Abby S. Kazley, Kit N. Simpson, Kenneth D. Chavin, Prabhakar Baliga

The biocompatibility of neutral pH, low-GDP peritoneal dialysis solutions: benefit at bench, bedside, or both? Jeffrey Perl, Sharon J. Nessim, Joanne.

Survival of propensity matched incident peritoneal and hemodialysis patients in a United States health care system Victoria A. Kumar, Margo A. Sidell,

E.F. Vonesh, J.J. Snyder, R.N. Foley, A.J. Collins

Volume 68, Issue 4, Pages (October 2005)

Presentation transcript:

Volume 84, Issue 5, Pages 969-979 (November 2013) The impact of neutral-pH peritoneal dialysates with reduced glucose degradation products on clinical outcomes in peritoneal dialysis patients Yeoungjee Cho, David W. Johnson, Sunil V. Badve, Jonathan C. Craig, Giovanni F.M. Strippoli, Kathryn J. Wiggins Kidney International Volume 84, Issue 5, Pages 969-979 (November 2013) DOI: 10.1038/ki.2013.190 Copyright © 2013 International Society of Nephrology Terms and Conditions

Figure 1 Flowchart indicating the number of citations retrieved by individual searches and the final number of included studies; reasons for exclusions are provided. PD, peritoneal dialysis; PET, peritoneal equilibration test; RCT, randomized controlled trial. Kidney International 2013 84, 969-979DOI: (10.1038/ki.2013.190) Copyright © 2013 International Society of Nephrology Terms and Conditions

Figure 2 Risk of bias summary of all included studies. Kidney International 2013 84, 969-979DOI: (10.1038/ki.2013.190) Copyright © 2013 International Society of Nephrology Terms and Conditions

Figure 3 Effect of neutral-pH, low-GDP peritoneal dialysis solution on residual renal function. (a) Trials with follow-up duration of 12 months and up to 24 months; (b) trials with follow-up duration 24 months and beyond. CI, confidence interval; GDP, glucose degradation product; SMD, standardized mean difference. Kidney International 2013 84, 969-979DOI: (10.1038/ki.2013.190) Copyright © 2013 International Society of Nephrology Terms and Conditions

Figure 4 Effect of neutral-pH, low-GDP peritoneal dialysis solution on residual renal function (all trials). CI, confidence interval; GDP, glucose degradation product. Kidney International 2013 84, 969-979DOI: (10.1038/ki.2013.190) Copyright © 2013 International Society of Nephrology Terms and Conditions

Figure 5 Effect of neutral-pH, low–GDP on daily urine volume (all trials). CI, confidence interval; GDP, glucose degradation product. Kidney International 2013 84, 969-979DOI: (10.1038/ki.2013.190) Copyright © 2013 International Society of Nephrology Terms and Conditions

Figure 6 Effect of neutral-pH, low-GDP peritoneal dialysis solution on peritonitis rate. CI, confidence interval; GDP, glucose degradation product. Kidney International 2013 84, 969-979DOI: (10.1038/ki.2013.190) Copyright © 2013 International Society of Nephrology Terms and Conditions